KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Taxes (2016 - 2020)

Supernus Pharmaceuticals has reported Current Taxes over the past 5 years, most recently at $25.1 million for Q2 2020.

  • Quarterly Current Taxes rose 836.87% to $25.1 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $25.1 million through Jun 2020, up 836.87% year-over-year, with the annual reading at $2.4 million for FY2019, 80.26% down from the prior year.
  • Current Taxes was $25.1 million for Q2 2020 at Supernus Pharmaceuticals, up from $9.1 million in the prior quarter.
  • Over five years, Current Taxes peaked at $25.1 million in Q2 2020 and troughed at $7000.0 in Q4 2016.
  • The 5-year median for Current Taxes is $7.5 million (2017), against an average of $8.9 million.
  • Year-over-year, Current Taxes soared 227585.71% in 2017 and then tumbled 80.26% in 2019.
  • A 5-year view of Current Taxes shows it stood at $7000.0 in 2016, then soared by 227585.71% to $15.9 million in 2017, then fell by 22.34% to $12.4 million in 2018, then tumbled by 80.26% to $2.4 million in 2019, then surged by 925.46% to $25.1 million in 2020.
  • Per Business Quant, the three most recent readings for SUPN's Current Taxes are $25.1 million (Q2 2020), $9.1 million (Q1 2020), and $2.4 million (Q4 2019).